Fig 1.
Contemporary Puerto Rican ZIKV isolate productively infects human DCs.
moDCs were infected with ZIKV PR-2015 at MOI of 1 and assessed for viral replication at indicated hours post-infection. (A) Viral RNA was detected in cell lysates by qRT-PCR for ZIKV E protein RNA. Gene expression is shown as relative expression after normalization to GAPDH levels in each respective sample (n = 7 donors). (B) Viral titers in supernatants of ZIKV-infected moDCs as determined by focus forming assay (FFA; n = 8 donors). FFU, focus forming units. (C) Percent infected cells as assessed by ZIKV E protein staining (4G2-APC antibody) and flow cytometry (n = 9 donors). (D) ImageStream analysis of ZIKV-infected moDCs labeled for viral E protein at 48hpi. Images of individual cells highlighted in the flow plot are represented and ordered according to E protein staining intensity. (E) moDCs were infected with ZIKV PR-2015 at MOI of 1 for 1hr on ice, washed extensively, and bound virus was quantitated by qRT-PCR for ZIKV RNA. Gene expression is represented as relative expression after normalization to GAPDH levels in each respective sample and shown as the mean +/- SD from 6–9 donors. See also S1 Fig.
Fig 2.
Differential infection of human DCs by evolutionarily distinct ZIKV strains.
moDCs were infected with PR-2015, P6-1966, MR-1947, or Dak-1984 at MOI of 1 and assessed for viral replication at the indicated hours post-infection. (A) Infectious virus release into the supernatant was determined by FFA. Shown as the mean +/- SEM from 6–9 donors. (B) Infectious virus release for 6 of the individual donors summarized in panel A. (C) Percent infected cells assessed by ZIKV E protein staining and flow cytometry. Shown as the mean +/- SEM from 6–9 donors. (D) Percent infected cells in 6 of the individual donors summarized in panel C. (E) Cell viability of infected moDCs assessed by Ghost Red 780 (Tonbo) viability staining and flow cytometry. Shown as the mean +/- SEM from 6–9 donors. Statistical significance (p< 0.05) was determined using a two-way ANOVA with comparisons made to mock-infected cells. See also S1 Table.
Fig 3.
ZIKV infection minimally activates human DCs.
(A) moDCs were left uninfected (“Mock”) or infected with PR-2015, P6-1966, MR-1947, or Dak-1984 at MOI of 1 (n = 6–8 donors). Cells were collected at 48hpi and labeled for ZIKV E protein and indicated DC activation markers. Cells were categorized as being viral E protein- or viral E protein+ and activation marker surface expression quantitated by flow cytometry. Values are represented as median fluorescence intensity (MFI) for each individual donor with uninfected and ZIKV infected samples from the same donor connected with a line. Statistical significance (p< 0.05) was determined using a Friedman test with comparisons made to donor-paired, uninfected cells. (B) moDCs infected with PR-2015 at MOI of 1 were stratified into “low” (n = 3 donors) and “high” (n = 5 donors) infection on the basis of viral E protein staining. MFIs are shown as the mean +/- SD. See also S3 Fig.
Fig 4.
ZIKV infection induces minimal pro-inflammatory cytokine production by DCs.
(A) moDCs were left untreated (“Mock”), transfected with RIG-I agonist (10ng/1e5 cells), or infected with PR-2015, P6-1966, MR-1947, or Dak-1984 at MOI of 1 (n = 7 donors). Supernatants were collected at 48hpi. (B, C) Monocytes (Mo) and myeloid DCs (mDCs) were left untreated (“Mock”), treated with LPS (100 ng/ml), or infected with PR-2015 at MOI of 1 (n = 5 donors). Supernatants were collected at 24hpi. (D) Plasmacytoid DCs (pDCs) were left untreated (“Mock”), treated with R848 (1 μg/ml), or infected with PR-2015 at MOI of 1 (n = 5 donors). Supernatants were collected at 24hpi. Cytokine production was assessed using multiplex bead array. Values for each individual donor are shown with the mean +/- SD. Statistical significance (p< 0.05) was determined using a Kruskal-Wallis test with comparisons made to untreated (“Mock”) cells. See also S2, S3, S4, and S5 Tables.
Fig 5.
ZIKV infection induces type I IFN transcription but inhibits translation.
moDCs were left untreated (“Mock”), treated with RIG-I agonist (10ng/1e5 cells), or infected with PR-2015, P6-1966, MR-1947, or Dak-1984 at MOI of 1. Supernatants were collected 24hrs (RIG-I agonist treatment) or 48hrs (ZIKV infection) later and IFNβ and IFNα (A) or IFNλ1 (B) production was assessed via multiplex bead array. Values for each individual donor are shown with the mean +/- SD (n = 7 donors). Statistical significance (p< 0.05) was determined using a Friedman test with comparisons made to donor-paired, mock-infected cells. A dashed line indicates the assay limit of detection. (C) moDCs were infected with ZIKV at MOI of 1 in the presence of anti-IFNAR2 blocking antibody. Cells were collected at 48hpi and labeled for ZIKV E protein, while release of infectious virus into the supernatants was determined by FFA. Values for each individual donor are shown with the mean +/- SD (n = 4 donors). A dashed indicates no change relative to infection in the absence of anti-IFNAR2 blocking antibody. (D) RNA was harvested from cells treated the same as for cytokine analysis and IFNB1 mRNA expression was determined by qRT-PCR. Gene expression was normalized to GAPDH transcript levels in each respective sample and represented as the log2 normalized fold increase above donor- and time point-matched untreated cells. Values for each individual donor are shown with the mean (n = 6–8 donors). (E) moDCs were treated with RIG-I agonist (10ng/1e5 cells, 18hrs) or infected with ZIKV PR-2015 (MOI 1 and 10, 48hrs) and analyzed for IFNB1 mRNA expression. Values for each individual donor are shown with the mean (n = 7 donors) (F) IFNβ and IFNα were measured in the supernatant (“Sup”) and whole cell lysate (“WCL”) of moDCs treated the same as in E. Values for each individual donor are shown with the mean (n = 7 donors). Statistical significance (p< 0.05) was determined using a Friedman test with comparisons made to donor-paired, mock-infected cells. (G) Uninfected or ZIKV PR-2015-infected moDCs (MOI 10, 48hpi) were treated with RIG-I agonist (10ng/1e5 cells, 18hrs) and IFNβ and IFNα were measured as in F. The data is shown as the fold-decrease from RIG-I agonist treatment alone with significance (P<0.05) determined using a Mann Whitney Test (n = 4 donors). Error bars represent the mean +/- SD. See also S4 Fig.
Fig 6.
ZIKV infection induces an antiviral state within human DCs.
moDCs were infected with ZIKV PR-2015, P6-1966, MR-1947, or Dak-1984 at MOI of 1 (n = 6–8 donors). Cells were collected at indicated hours post-infection and antiviral gene expression was determined by qRT-PCR. Gene expression was normalized to GAPDH transcript levels in each respective sample and represented as the averaged log2 normalized fold increase above donor and time-point matched uninfected cells. The averaged log10 normalized levels of infectious virus (FFU/mL) at each time point is depicted beneath the gene expression heat map. (A) RLR gene expression. (B) Antiviral effector gene expression. (C) moDCs were left untreated (“Mock”), treated with RIG-I agonist (10ng/1e5 cells), or infected with ZIKV PR-2015 (MOIs of 1 and 10) or MR-1947 (MOI 1). After 18hrs of agonist treatment or at 48hpi with ZIKV, whole-cell lysates were collected for western blot analysis of host antiviral effector protein expression. Western blots are shown for a single donor and are representative of data obtained from two donors. See also S5 Fig.
Fig 7.
Innate immune signaling restricts ZIKV viral replication within human DCs.
(A) moDCs were infected with PR-2015, P6-1966, MR-1947, or Dak-1984 at MOI of 1 (n = 4 donors). After viral attachment and entry at 1hpi, cells were treated with RIG-I agonist (10ng/1e5 cells), human IFNβ (100 IU/mL), or left untreated. (B) Supernatants were collected at 48hpi and assessed for infectious virus release by FFA. Values for each individual donor are shown with the mean +/- SD. Statistical significance (p< 0.05) was determined using a Friedman test with comparisons made to donor-paired, untreated, ZIKV-infected cells. The assay limit of detection is indicated with a dashed line.
Fig 8.
ZIKV antagonizes type I IFN signaling.
(A, B) A549 cells were infected with PR-2015, P6-1966, MR-1947, or Dak-1984 at MOIs of 0.1 and 1. At 48hpi, cells were pulse treated with 1000 IU/mL of recombinant human IFNβ for 30 minutes and whole-cell lysates were collected for western blot analysis of phospho-STAT1 (Tyr701), phospho-STAT2 (Tyr689), STAT1, STAT2, and GAPDH. Representative blots are shown from one of two independent experiments. Quantitation is shown below the representative blots, where intensity values are represented as the ratio of pSTAT:total STAT protein. (C) moDCs were infected with PR-2015 (MOI 10) and STAT1 and STAT2 signaling was assessed as in A and B. Data is representative of three donors from two independent experiments. Quantitation is shown to the right of the representative blots, where intensity values are represented as the ratio of pSTAT:total STAT protein.